Status:
UNKNOWN
Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Alcoholic Hepatitis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The patients of Severe Alcoholic Hepatitis (SAH) will be included in study based on inclusion and exclusion criteria. The patients will be then randomized in 3 groups for therapy. They will receive ei...
Eligibility Criteria
Inclusion
- Severe alcoholic hepatitis patients \[Maddrey's score \> 32\] aged between 18 to 65 years.
Exclusion
- Presence of active infections
- Acute Gastrointestinal bleed
- Hepatorenal syndrome
- Patient unwilling
- Discriminant Function \>90
- Autoimmune hepatitis
- Hepatitis B, Hepatitis C, Human immunodeficiency Virus cases
- Pregnancy
- Hemophagocytic lymphohistiocytosis (HLH)
- Hb\<8 and baseline White Blood Cell\>25000
Key Trial Info
Start Date :
September 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 27 2021
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT04066179
Start Date
September 7 2019
End Date
February 27 2021
Last Update
September 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India, 110070